Pharmacological management of Ewing sarcoma family of tumours

Expert Opinion on Pharmacotherapy

Volumn 5, Issue 6, 2004, Pages 1257-1270

  Rodriguez Galindo, Carlos ^a  

^a ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

Author keywords

Autologous haematopoietic stem cell transplantation; Children; Ewing sarcoma; Megatherapy; Therapy intensification

Indexed keywords

ALKYLATING AGENT; AMIFOSTINE; ANTINEOPLASTIC AGENT; BORTEZOMIB; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DEPSIPEPTIDE; DNA TOPOISOMERASE INHIBITOR; DOXORUBICIN; ERLOTINIB; ETOPOSIDE; EXATECAN; GEFITINIB; GRANULOCYTE COLONY STIMULATING FACTOR; GYRASE INHIBITOR; IFOSFAMIDE; IMATINIB; IRINOTECAN; MELPHALAN; RAPAMYCIN; TEMOZOLOMIDE; TEMSIROLIMUS; THIOTEPA; TOPOTECAN; TRABECTEDIN; UNINDEXED DRUG; VINCRISTINE;

CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER IMMUNOTHERAPY; CANCER LOCALIZATION; CANCER MORTALITY; CANCER SURVIVAL; CLINICAL TRIAL; DRUG MEGADOSE; EWING SARCOMA; HEMATOLOGIC MALIGNANCY; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; METASTASIS; OUTCOMES RESEARCH; REVIEW; SURVIVAL RATE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CLINICAL TRIALS; HUMANS; SARCOMA, EWING'S; TREATMENT OUTCOME;

EID: 3042853072     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.5.6.1257     Document Type: Review

References (126)

1. GURNEY JG, SEVERSON RK, DAVIS S, ROBISON LL: Incidence of cancer in children in the United States. Cancer (1995) 75:2186-2195.
2. DEHNER LP: Primitive neuroectodermal tumor and Ewing's sarcoma. Am. J. Surg. Pathol. (1993) 17:1-13.
3. DE ALAVA E, GERALD WL: Molecular biology of the Ewing's sarcoma/primitive neuroectodermal tumor family. J. Clin. Oncol. (2000) 18:204-213.
4. DELATTRE O, ZUCMAN J, MELOT T et al.: The Ewing family of tumors: a subgroup of small-round-cell tumors defined by specific chimeric transcripts. N. Engl. J. Med. (1994) 331:294-299.
5. COTTERILL SJ, AHRENS S, PAULUSSEN M et al.: Prognostic factors in Ewing's tumor of bone: analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J. Clin. Oncol. (2000) 18:3108-3114.
6. WIDHE B, WIDHE T: Initial symptoms and clinical features in osteosarcoma and Ewing sarcoma. J. Bone Joint Surg. Am. (2000) 82:667-674.
7. RANEY RB, ASMAR L, NEWTON WA et al.: Ewing's sarcoma of soft tissues in childhood: a report from the Intergroup Rhabdomyosarcoma Study, 1972-1991. J. Clin. Oncol. (1997) 15:574-582.
8. BACCI G, FERRARI S, BERTONI F et al.: Prognostic factors in nonmetastatic Ewing's sarcoma of bone treated with adjuvant chemotherapy: analysis of 359 patients at the Istituto Ostopedico Rizzoli. J. Clin. Oncol. (2000) 18:4-11.
9. WEST DC, GRIER HE, SWALLOW MM, DEMETRI GD, GRANOWETTER L, SKLAR J: Detection of circulating tumor cells in patients with Ewing's sarcoma and peripheral primitive neuroectodermal tumor. J. Clin. Oncol. (1997) 15:583-588.
10. RODRIGUEZ-GALINDO C, BILLUPS CA, KUN LE et al.: Survival after recurrence of Ewing tumors: The St Jude Children's Research Hospital Experience, 1979-1999. Cancer (2002) 94:561-569.
11. GRIER HE, KRAILO MD, TARBELL NJ et al.: Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N. Engl. J. Med. (2003) 348:694-701.
12. PICCI P, BOHLING T, BACCI G et al.: Chemotherapy-induced tumor necrosis as a prognostic factor in localized Ewing's sarcoma of the extremities. J. Clin. Oncol. (1997) 15:1553-1559.
13. PAULUSSEN M, AHRENS S, DUNST J et al.: Localized Ewing tumor of bone: final results of the Cooperative Ewing's Sarcoma Study CESS-86. J. Clin. Oncol. (2001) 19:1818-1829.
14. GINSBERG JP, DE ALAVA E, LADANYI M et al.: EWS-FLI1 and EWS-ERG gene fusions are associated with similar clinical phenotypes in Ewing's sarcoma. J. Clin. Oncol. (1999) 17:1809-1814.
15. DE ALAVA E, KAWAI A, HEALEY JH et al.: EWS-FLI1 fusion transcript structure is an independent determinant of prognosis in Ewing's sarcoma. J. Clin. Oncol. (1998) 16:1248-1255.
16. ZOUBEK A, DOCKHORN-DWORNICZAK B, DELATTRE O et al.: Does expression of different EWS chimeric transcripts define clinically distinct risk groups of Ewing tumor patients? J. Clin. Oncol. (1996) 14:1245-1251.
17. ZOUBEK A, LADENSTEIN R, WINDHAGER R et al.: Predictive potential of testing for bone marrow involvement in Ewing tumor patients by RT-PCR: a preliminary evaluation. Int. J. Cancer (1998) 79:56-60.
18. FAGNOU C, MICHON J, PETER M et al.: Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. J. Clin. Oncol. (1998) 16:1707-1711.
19. SCHLEIERMACHER G, PETER M, OBERLIN O et al.: Increased risk of systemic relapses associated with bone marrow micrometastasis and circulating tumor cells in localized Ewing tumor. J. Clin. Oncol. (2003) 21:85-91.
20. NESBIT ME, GEHAN EA, BURGERT EO et al.: Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: a long-term follow-up of the first intergroup study. J. Clin. Oncol. (1990) 8:1664-1674.
21. BURGERT EO, NESBIT ME, GARNSEY LA et al.: Multimodal therapy for the management of nonpelvic, localized Ewing's sarcoma of bone: Intergroup Study IESS-II. J. Clin. Oncol. (1990) 8:1514-1524.
22. HAYES FA, THOMPSON EI, MEYER WH et al.: Therapy for localized Ewing's sarcoma of bone. J. Clin. Oncol. (1989) 7:208-213.
23. JÜRGENS H, EXNER U, GADNER H et al.: Multidisciplinary treatment of primary Ewing's sarcoma of bone. Cancer (1988) 61:23-32.
24. CRAFT AW, COTTERILL SJ, BULLIMORE JA, PEARSON D: Long-term results from the first UKCCSG Ewing's tumour study (ET-1). Eur. J. Cancer (1997) 33:1061-1069.
25. CRAFT A, COTTERILL S, MALCOLM A et al.: Ifosfamide-containig chemotherapy in Ewing's sarcoma: the second United Kingdom Children's Cancer Study Group and the Medical Research Council Ewing's Tumor Study. J. Clin. Oncol. (1998) 16:3628-3633.
26. LILLEY ER, ROSENBERG MC, ELION GB, COLVIN M, BIGNER DD, FRIEDMAN HS: Synergistic interactions between cyclophosphamide or melphalan and VP-16 in a human rhabdomyosarcoma xenograft. Cancer Res. (1990) 50:284-287.
27. YAZAWA Y, TAKAGI T, ASAKURA S, SUZUKI K, KANO Y: Effects of 4-hydroperoxy ifosfamide in combination with other anticancer agents on human cancer cell lines. Orthop. Sci. (1999) 4:231-237.
28. MISER JS, KINSELLA TJ, TRICHE TJ et al.: Ifosfamide with mesna uroprotection and etoposide: an effective regimen in the treatment of recurrent sarcomas and other tumors of children and young adults. J. Clin. Oncol. (1987) 5:1191-1198.
29. KUNG FH, PRATT CB, VEGA RA et al.: Ifosfamide/Etoposide combination in the treatment of recurrent malignant solid tumors of childhood. Cancer (1993) 71:1898-1903.
30. CLARK PI, SLEVIN ML, JOEL SP et al.: A randomized trial of two etoposide schedules in small-cell lung cancer: the infuence of pharmacokinetics on efficacy and toxicity. J. Clin. Oncol. (1994) 12:1427-1435.
31. KUROWSKI V, WAGNER T: Comparative pharmacokinetics of ifosfamide, 4-hydroxyifosfamide, chloroacetylaldehyde, and 2- and 3-dechloroethylifosfamide in patients on fractionated intravenous ifosfamide therapy. Cancer Chemother. Pharmacol. (1993) 33:36-42.
32. BODDY AV, YULE SM, WYLLIE R, PRICE L, PEARSON AD, IDLE JR: Pharmacokinetics and metabolism of ifosfamide administered as a continuous infusion in children. Cancer Res. (1993) 53:3758-3764.
33. COMANDONE A, LEONE L, OLIVA C et al.: Pharmacokinetics of ifosfamide administered according to three different schedules in metastatic soft tissue and bone sarcomas. J. Chemother. (1998) 10:385-393.
34. MEYER WH, KUN L, MARINA N: Ifosfamide plus etoposide in newly diagnosed Ewing's sarcoma of bone. J. Clin. Oncol. (1992) 10:1737-1742.
35. CRAFT AW, PAULUSSEN M, DOUGLAS C, MAPP T, LEWIS IB, JURGENS H: EICESS 92- Early results of an international Ewings tumour study. Med. Pediatr. Oncol. (2000) 35:191 (Abstract).
36. KUSHNER BH, MEYERS PA, GERALD WL et al.: Very high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J. Clin. Oncol. (1995) 13:2796-2804.
37. KUSHNER BH, LAQUAGLIA MP, WOLLNER N et al.: Desmoplastic small-round cell tumor: prolonged progression-free survival with aggressive multi-modality therapy. J. Clin. Oncol. (1996) 14:1526-1531.
38. MARINA NM, PAPPO AS, PARHAM DM et al.: Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round cell tumor: a feasibility study at St. Jude Children's Research Hospital. J. Clin. Oncol. (1999) 17:180-190.
39. GRANOWETTER L, WOMER R, DEVIDAS M et al.: Comparison of dose intensified and standard dose chemotherapy for the treatment of non-metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone and soft tissue: a Pediatric Oncology Group-Children's Cancer Group Phase III trial. Med. Pediatr. Oncol. 37:172 (Abstract).
40. WOMER RB, DALLER RT, FENTON JG, MISER JS: Granulocyte colony stimulating factor permits dose intensification by interval compression in the treatment of Ewing's sarcomas and soft tissue sarcomas in children. Eur. J. Cancer (2000) 36:87-94.
41. RODRIGUEZ-GALINDO C, POQUETTE CA, MARINA NM et al.: Hematologic abnormalities and acute myeloid leukemia in children and adolescents administered intensified chemotherapy for the Ewing sarcoma family of tumors. J. Pediatr. Hematol. Oncol. (2000) 22:321-329.
42. MISER JS, KRAILO M, MEYERS P et al.: Metastatic Ewing's sarcoma (ES) and primitive neuroectodermal tumor (PNET) of bone: failure of new regimens to improve outcome. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1996) 15:467 (Abstract).
43. KUSHNER BH, HELLER G, CHEUNG NK et al.: High risk of leukemia after short-term dose-intensive chemotherapy in young patients with solid tumors. J. Clin. Oncol. (1998) 16:3016-3020.
44. SANDOVAL C, MEYER WH, PARHAM DM et al.: Outcome in 43 children presenting with metastatic Ewing sarcoma: The St Jude Children's Research Hospital Experience, 1962 to 1992. Med. Pediatr. Oncol. (1996) 26:180-185.
45. PAULUSSEN M, AHRENS S, BURDACH S et al.: Primary metastatic (stage IV) Ewing tumor: survival analysis of 171 patients from the EICESS studies. Ann. Oncol. (1998) 9:275-281.
46. PAULUSSEN M, AHRENS S, CRAFT AW et al.: Ewing's tumors with primary lung metastases: survival analysis of 114 (European Intergroup) Cooperative Ewing's Sarcoma Studies patients. J. Clin. Oncol. (1998) 16:3044-3052.
47. SAARINEN UM, HOVI L, MAKIPERNAA A, RIIKONEN P: High-dose thiotepa with autologous bone marrow rescue in pediatric solid tumors. Bone Marrow Transplant. (1991) 8:369-376.
48. WEAVER CH, BENSINGER WI, APPELBAUM FR et al.: Phase I study of high-dose busulfan, melphalan and thiotepa with autologous stemm cell support in patients with refractory malignancies. Bone Marrow Transplant. (1994) 14:813-819.
49. SCHIFFMAN KS, BENSINGER WI, APPELBAUM FR et al.: Phase II study of high-dose busulfan, melphalan and thiotepa with autologous peripheral blood stem cell support in patients with malignant disease. Bone Marrow Transplant. (1996) 17:943-950.
50. STEWART DA, GYONYOR E, PATERSON AHG et al.: High-dose melphalan ± total body irradiation and autologous hematopoietic stem cell rescue for adult patients with Ewing's sarcoma or peripheral neuroectodermal tumor. Bone Marrow Transplant. (1996) 18:315-318.
51. BURDACH S, VAN KAICK B, LAWS HJ et al.: Allogeneic and autologous stem-cell transplantation in advanced Ewing tumors. An update after long-term follow-up from two centers of the European Intergroup Study EICESS. Ann. Oncol. (2000) 11:1451-1462.
52. BURDACH S, MEYER-BAHLURG A, LAWS HJ et al.: High-dose therapy for patients with primary multifocal and early relapsed Ewing's tumors: results of two consecutive regimens assessing the role of total-body irradiation. J. Clin. Oncol. (2003) 21:3072-3078.
53. MEYERS PA, KRAILO MD, LADANYI M et al.: High-dose melphalan, etoposide, total-body irradiation, and autologous stem-cell reconstitution as consolidation therapy for high-risk Ewing's sarcoma does not improve prognosis. J. Clin. Oncol. (2001) 19:2812-2820.
54. KUSHNER BH, MEYERS PA: How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering Experience and a literature review. J. Clin. Oncol. (2001) 19:870-880.
55. LADENSTEIN R, HARTMANN O, PINKERTON R et al.: A multivariate and matched pair analysis on high-risk Ewing tumo (ET) patients treated by megatherapy (MGT) and stem cell reinfusion (SCR) in Europe. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (1999) 18:555 (Abstract).
56. DAVIES SM, DEFOR TE, WEIGEL BJ et al.: High dose busulfan-based chemotherapy with autologous stem cell transplantation (ASCT) for high risk Ewing's sarcoma family of tumors. Proc. Ann. Meet. Am. Soc. Clin. Oncol. (2001) 20:364 (Abstract).
57. LADENSTEIN R, LASSET C, PINKERTON R et al.: Impact of megatherapy in children with high-risk Ewing's tumours in complete remission: a report from the EBMT solid tumour registry. Bone Marrow Transplant. (1995) 15:697-705.
58. CHAMPLIN R, KHOURI I, KOMBLAU S, MOLIDREM J, GIRALT S: Reinventing bone marrow transplantation. Nonmyeloablative preparative regimens and induction of graft-vs-malignancy effect. Oncology (1999) 13:621-628.
59. DISIS ML, CHEEVER MA: Oncogenic proteins as tumor antigens. Curr. Opin. Immunol. (1996) 8:637-642.
60. CHILDS RW, CLAVE E, TISDALE J, PLANTE M, HENSEL N, BARRETT J: Successful treatment of metastatic renal cell carcinoma with a nonmyeloablative allogeneic peripheral-blood progenitor-cell transplant: evidence for a graft-versus-tumor effect. J. Clin. Oncol. (1999) 17:2044-2050.
61. AHRENS S, HOFFMAN C, JABAR S et al.: Evaluation of prognostic factors in a tumor volume-adapted treatment strategy for localized Ewing sarcoma of bone: the CESS 86 experience. Med. Pediatr. Oncol. (1999) 32:186-195.
62. ROSITO P, MANCINI A, RONDELLI R et al.: Italian cooperative study for the treatment of children and young adults with localized Ewing sarcoma of bone. A preliminary report of 6 years of experience. Cancer (1999) 86:421-428.
63. SHANKAR AG, PINKERTON CR, ATRA A et al.: Local therapy and other factors influencing site of relapse in patients with localised Ewing's sarcoma. Eur. J. Cancer. (1999) 35:1698-1704.
64. EVANS RG, NESBIT ME, GEHAN EA et al.: Multimodal therapy for the management of localized Ewing's sarcoma of pelvic and sacral bones: a report from the Second Intergroup Study. J. Clin. Oncol. (1991) 9:1173-1180.
65. BACCI G, PICCI P, FERRARI S et al.: Neoadjuvant chemotherapy for Ewing's sarcoma of bone. No benefit observed after adding ifosfamide and etoposide to vincristine, actinomycin, cyclophosphamide, and doxorubicin in the maintenance phase. Results of two sequential studies. Cancer (1998) 82:1174-1183.
66. HOFFMAN C, AHRENS S, DUNST J et al.: Pelvic Ewing sarcoma: a retrospective analysis of 241 cases. Cancer (1999) 85:869-877.
67. BARBIERI E, EMILIANI E, ZINI G et al.: Combined therapy of localized Ewing's sarcoma of bone: analysis of results in 100 patients. Int. J. Radiat. Oncol. Biol. Phys. (1990) 19:1165-1170.
68. OZAKI T, HILLMAN A, HOFFMAN C et al.: Significance of surgical margin on the prognosis of patients with Ewing's sarcoma. Cancer (1996) 78:892-900.
69. KUTTESCH JF, WEXLER LH, MARCUS RB et al.: Second malignancies after Ewing's sarcoma: radiation dose-dependency of secondary sarcomas. J. Clin. Oncol. (1996) 14:2818-2825.
70. ARAI Y, KUN LE, BROOKS T et al.: Ewing's sarcoma: Local tumor control and patterns of failure following limited-volume radiation therapy. Int. J. Radiat. Oncol. Biol. Phys. (1991) 21:1501-1508.
71. RODRIGUEZ-GALINDO C, RADOMSKI KM, STEWART CF, FURMAN W, SANTANA VM, HOUGHTON PJ: Clinical use of topoisomerase I inhibitors in anticancer treatment. Med. Pediatr. Oncol. (2000) 35:385-402.
72. PRATT CB, STEWART CF, SANTANA VM et al.: Phase I study of topotecan for pediatric patients with malignant solid tumors. J. Clin. Oncol. (1994) 12:539-543.
73. NITSCHKE R, PARKHURST J, SULLIVAN J, HARRIS MB, BERNSTEIN M, PRATT C: Topotecan in pediatric patients with recurrent and progressive solid tumors: a Pediatric Oncology Group Phase II study. J. Pediatr. Hematol. Oncol. (1998) 20:315-318.
74. TUBERGEN DG, STEWART CF, PRATT CB et al.: Phase I and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: a Pediatric Ontology Group study. J. Pediatr. Hematol. Oncol. (1996) 18:352-361.
75. FRANGOUL H, AMES MM, MOSHER RB et al.: Phase I study of topotecan administered as a 21-day continuous infusion in children with recurrent solid tumors: a report from the Children's Cancer Group. Clin. Cancer Res. (1999) 5:3956-3962.
76. FURMAN WL, STEWART CF, POQUETTE CA et al.: Direct translation of a protracted irinotecan schedule from a xenograft model to a Phase I trial in children. J. Clin. Oncol. (1999) 17:1815-1824.
77. BLANEY S, BERG SL, PRATT C et al.: A Phase I study of irinotecan in pediatric patients: a Pediatric Oncology Group Study. Clin. Cancer Res. (2001) 7:32-37.
78. VASSAL G, DOZ F, FRAPPAZ D et al.: A Phase I study of irinotecan as a 3-week schedule in children with refractory or recurrent solid tumors. J. Clin. Oncol. (2003) 21:3844-3852.
79. COSETTI M, WEXLER LH, CALLEJA E et al.: Irinotecan for pediatric solid tumors: The Memorial Sloan-Kettering experience. J. Pediatr. Hematol. Oncol. (2003) 24:101-105.
80. SAYLORS RL, STINE KC, SULLIVAN J et al.: Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: a pediatric oncology group (POG) Phase II study. J. Clin. Oncol. (2001) 19:3463-3469.
81. BERNSTEIN ML, GOORIN A, DEVIDAS M et al.: Topotecan and topotecan, cyclophosphamide window therapy in patients (pts) with Ewing sarcoma (EWS) metastatic at diagnosis: an Intergroup Pediatric Oncology Group (POG) study (P-9457). Med. Pediatr. Oncol. (2001) 37:176 (Abstract).
82. WAGNER LM, CREWS KR, IACONO LC et al.: Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors. Clin. Cancer Res. (2004) 10:840-848.
83. TRIPETT T, FURMAN W, AQUINO V et al.: Phase I study of DX-8951f in pediatric patients with advanced solid tumors. Proc. Ann. Am. Soc. Clin. Oncol. (2001) 20:376 (Abstract).
84. DRUKER BJ, LYDON NB: Lessons learned from the development of an abl tyrosine kinase inhibitor fro chronic myelogenous leukemia. J. Clin. Invest. (2001) 105:3-7.
85. RICOTTI E, FAGIOLI F, GARELLI E et al.: c-kit is expressed in soft tissue sarcoma of neuroectodermic origin and its ligand prevents apoptosis of neoplastic cells. Blood (1998) 91:2397-2405.
86. HOTFILDER M, LANVERS C, JÜRGENS H et al.: c-KIT-expressing Ewing tumour cells are insensitive to imatinib mesylate (STI571). Cancer Chemother. Pharmacol. (2002) 50:167-169.
87. SMITHEY BE, PAPPO AS, HILL D: A c-kit expression in pediatric solid tumors. Am. J. Surg. Pathol. (2002) 26: 486-492.
88. SCOTLANDI K, MANARA MC, STRAMMIELLO R et al.: c-kit receptor expression in Ewing's sarcoma: lack of prognostic value but therapeutic targeting opportunities in appropriate conditions. J. Clin. Oncol. (2003) 21:1952-1960.
89. YE D, MAITRA A, TIMMONS CF et al.: The epidermal growth factor receptor HER2 is not a major therapeutic target in Ewing sarcoma. J. Pediatr. Hematol. Oncol. (2003) 25:459-466.
90. IZBICKA E, LAWRENCE R, RAYMOND E et al.: In vitro antitumor activity of the novel marine agent, ecteinascidin-743 (ET-743, NSC-648766) against human tumors explanted from patients. Ann. Oncol. (1998) 9:981-987.
91. YOVINE A, RIOFRIO M, BLAY JY et al.: Phase II study of ecteinascidin-743 in advanced pretreated soft tissue sarcoma patients. J. Clin. Oncol. (2004) 22:890-899.
92. MITSIADES N, POULAKI V, MITSIADES C, TSOKOS M: Ewing's sarcoma family of tumors are sensitive to tumor necrosis factor-related apoptosis-inducing ligand and express death receptor 4 and death receptor 5. Cancer Res. (2001) 61:2704-2712.
93. VAN VALEN F, FULDA S, TRUCKENBORD B et al.: Apoptotic responsiveness of the Ewing's sarcoma family of tumours to tumour necrosis factor-related apoptosis-inducing ligand (TRAIL). Int. J. Cancer (2000) 88:252-259.
94. VAN VALEN F, FULDA S, SCHAFER K-L et al.: Selective and nonselective toxicity of TRAIL/Apo2L combined with chemotherapy in human bone tumour cells versus normal human cells. Int. J. Cancer (2003) 107:929-940.
95. WALCZAK H, MILLER RE, ARIAIL K et al.: Tumoricidal activity of tumor necrosis factor-related apoptosis-inducing ligand in vivo. Nat. Med. (1999) 5:157-163.
96. PAN G, NI J, WEI YF, YU G, GENTZ R, DIXIT VM: an antagonist decoy receptor and a death domain-containing receptor for TRAIL. Science (1997) 277:815-818.
97. JO M, KIM TH, SEOL DW et al.: Apoptosis induced in normal human hepatocytes by tumor necrosis factor-related apoptosis-inducing ligand. Nat. Med. (2000) 6:564-567.
98. NITSCH R, BECHMANN I, DEISZ RA et al.: Human brain-cell death induced by tumour-necrosis factor-related apoptosis-inducing ligand (TRAIL). Lancet (2000) 356:827-828.
99. FANGER NA, MALISZEWSKI CR, SCHOOLEY K, GRIFFITH TS: Human dendritic cells mediate cellular apoptosis via tumor necrosis factor-related apoptosis-inducing ligand (TRAIL). J. Exp. Med. (1999) 190:1155-1164.
100. SANCEAU J, POUPON M-F, DELATTRE O, SASTRE GARAU X, WIETZERBIN J: Strong inhibition of Ewing tumor xenograft growth by combination of human interferon-alpha or interferon-beta with ifosfamide. Oncogene (2002) 21:7700-7709.
101. ABADIE A, BESANCON F, WIETZERBIN J: Type I interferon and TNFa cooperate with Type II interferon for TRAIL induction and triggering of apoptosis in SK-N-MC EWING tumor cells. Oncogene (2004) Apr 12 [Epub ahead of print].
102. MARKS PA, RICHON VM, BRESLOW R, RIFKIND RA: Histone deacetylase inhibitors as new cancer drugs. Curr. Opin. Oncol. (2001) 13:477-483.
103. PEART MJ, TAINTON KM, RUEFLI AA et al.: Novel mechanisms of apoptosis induced by histone deacetylase inhibitors. Cancer Res. (2003) 63:4460-4471.
104. BANNISTER AJ, MISKA EA: Regulation of gene expression by transcription factor acetylation. Cell. Mol. Life Sci. (2000) 57:1184-1192.
105. JABOIN J, WILD J, HAMIDI H et al.: MS-27-275, an inhibitor of histone deacetylase, has marked in vitro and in vivo antitumor activity against pediatric solid tumors. Cancer Res. (2002) 62:6108-6115.
106. HAHM KB, CHO K, LEE C et al.: Repression of the gene encoding the TGF-b Type II receptor is a major target of the EWING's SARCOMA-FLI1 oncoprotein. Nat. Genet. (1999) 23:222-227.
107. TORETSKY JA, KALEBIC T, BLAKESLEY V, LEROITH D, HELMAN LJ: The insulin-like growth factor-I receptor is required for EWS/FLI-1 transformation of fibroblasts. J. Biol. Chem. (1997) 272:30822-30827.
108. BENINI S, MANARA MC, BALDINI N et al.: Inhibition of Insulin-like growth Factor I receptor increases the antitumor activity of doxorubicin and vincristine against Ewing's sarcoma cells. Clin. Cancer Res. (2001) 7:1790-1797.
109. TORETSKY JA, THAKAR M, ESKENAZI AE, FRANTZ CN: Phosphoinositide 3-hydroxide kinase blockade enhances apoptosis in the Ewing's sarcoma family of tumors. Cancer Res. (1999) 59:5745-5750.
110. BENINI S, MANARA MC, CERISANO V et al.: Contribution of MEK/MAPK and PI3-K signaling pathway to the malignant behavior of Ewing's sarcoma cells: therapeutic prospects. Int. J. Cancer (2004) 108:358-366.
111. HIDALGO M, ROWINSKY EK: The rapamycin-sensitive signal transduction pathway as a target for cancer therapy. Oncogene (2000) 19:6680-6686.
112. MATEO-LOZANO S, TIRADO OM, NOTARIO V: Rapamycin induces the fusion-type independent downregulation of the EWS/FLI-1 proteins and inhibits Ewing's sarcoma cell proliferation. Oncogene (2003) 22:9282-9287.
113. MATSUMOTO Y, TANAKA K, NAKATANI F, MATSUNOBU T, MATSUDA S, IWAMOTO Y: Down-regulation and forced expression of EWS-Fli1 fusion gene results in changes in the expression of G(1) regulatory genes. Br. J. Cancer (2001) 84:768-775.
114. MATSUNOBU T, TANAKA K, MATSUMOTO Y, NAKATANI F, SAKIMURA R, HANADA M: The prognostic and therapeutic relevance of p27-kip1 in Ewing's family tumors. Clin. Cancer Res. (2004) 10:1003-1012.
115. PAGANO M, TAM SW, THEODORAS AM et al.: Role of the ubiquitin-proteasome pathway in regulating abundance of the cyclin-dependent kinase inhibitor p27. Science (1995) 269:682-685.
116. VOORHEES PM, DEES EC, O'NEIL B, ORLOWSKI RZ: The proteasome as a target for cancer therapy. Clin. Cancer Res. (2003) 9:6316-6325.
117. FULDA S, KUFER MU, MEYER E, VAN VALEN F, DOCKHORN-DWORNICZAK B, DEBATIN K-M: Sensitization for death receptor- or drug-induced apoptosis by re-expression of caspase-8 through demethylation or gene transfer. Oncogene (2001) 20:5865-5877.
118. MACKALL C, BERZOFSKY J, HELMAN LJ: Targeting tumor specific translocations in sarcomas in pediatric patients for immunotherapy. Clin. Orthop. (2000) 373:25-31.
119. MAKSIMENKO A, LAMBERT G, BERTRAND JR, FATTAL E, COUVREUR P, MALVY C: Therapeutic potentialities of EWS-Fli-1 mRNA-targeted vectorized antisense oligonucleotides. Ann. NY Acad. Sci. (2003) 1002:72-77.
120. SANTANA VM, ZAMBONI WC, KIRSTEIN MN et al.: A pilot study of protracted topotecan dosing using a pharmacokinetically guided dosing approach in children with solid tumors. Clin. Cancer Res. (2003) 9:633-640.
121. BLANEY SM, NEEDLE MN, GILLESPIE A et al.: Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: a collaborative Pediatric Branch, National Cancer Institute, and Children's Cancer Group Study. Clin. Cancer Res. (1998) 4:357-360.
122. ATHALE UH, STEWART C, KUTTESCH JF et al.: Phase I study of combination topotecan and carboplatin in pediatric solid tumors. J. Clin. Oncol. (2001) 20:88-95.
123. WELLS RJ, REID JM, AMES MM et al.: Phase I trial of cisplatin and topotecan in children with recurrent solid tumors: Children's Cancer Group Study 0942. J. Pediatr. Hematol. Oncol. (2002) 24:89-93.
124. KUSHNER BH, KRAMER K, MEYERS PA, WOLLNER N, CHEUNG N-K: V. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors. Med. Pediatr. Oncol. (2000) 35: 468-474.
125. MUGISHIMA H, MATSUNAGA T, YAGI K et al.: Phase I study of irinotecan in pediatric patients with malignant solid tumors. J. Pediatr. Hematol. Oncol. (2002) 24:94-100.
126. SOUID AK, DUBOWY RL, BLANEY SM, HERSHON SM, SULLIVAN J, MCLEOD WD, BERNSTEIN ML: Phase I clinical and pharmacologic study of weekly cisplatin and irinotecan combined with amifostine for refractory solid tumors. Clin. Cancer Res. (2003) 9:703-710.